195 related articles for article (PubMed ID: 26208487)
21. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
22. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
Godinho MF; Sieuwerts AM; Look MP; Meijer D; Foekens JA; Dorssers LC; van Agthoven T
Br J Cancer; 2010 Oct; 103(8):1284-91. PubMed ID: 20859285
[TBL] [Abstract][Full Text] [Related]
23. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
[TBL] [Abstract][Full Text] [Related]
24. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
25. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
[TBL] [Abstract][Full Text] [Related]
26. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract][Full Text] [Related]
27. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
28. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
29. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
[TBL] [Abstract][Full Text] [Related]
30. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
31. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
32. MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer.
Tian Y; Chen ZH; Wu P; Zhang D; Ma Y; Liu XF; Wang X; Ding D; Cao XC; Yu Y
Adv Sci (Weinh); 2023 Apr; 10(12):e2204819. PubMed ID: 36815359
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.
Tu SH; Chang CC; Chen CS; Tam KW; Wang YJ; Lee CH; Lin HW; Cheng TC; Huang CS; Chu JS; Shih NY; Chen LC; Leu SJ; Ho YS; Wu CH
Breast Cancer Res Treat; 2010 Jun; 121(3):539-53. PubMed ID: 19655245
[TBL] [Abstract][Full Text] [Related]
34. Endocrine therapy: defining the path of least resistance.
Stone A; Musgrove EA
Breast Cancer Res; 2014 May; 16(3):101. PubMed ID: 25928145
[TBL] [Abstract][Full Text] [Related]
35. Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.
Ali A; Creevey L; Hao Y; McCartan D; O'Gaora P; Hill A; Young L; McIlroy M
Breast Cancer Res; 2015 Sep; 17(1):123. PubMed ID: 26341737
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
37. Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells.
You D; Jung SP; Jeong Y; Bae SY; Lee JE; Kim S
BMB Rep; 2017 Dec; 50(12):615-620. PubMed ID: 28855026
[TBL] [Abstract][Full Text] [Related]
38. Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway.
He L; She C; Jiang S; Qi Z; Deng Z; Ji L; Cui Y; Wu J
Biol Direct; 2024 Mar; 19(1):21. PubMed ID: 38459605
[TBL] [Abstract][Full Text] [Related]
39. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
Fiorillo M; Sotgia F; Sisci D; Cappello AR; Lisanti MP
Oncotarget; 2017 Mar; 8(12):20309-20327. PubMed ID: 28411284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
